Across TCGA pan-cancer cohorts, SMYD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMYD3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SMYD3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMYD3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and GBM are the cancer types where SMYD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	1.000	0.329	.001	15	view →
HNSC	OS	Quartile	All	0.176	0.964	.017	13	view →
GBM	DFS	Median	All	0.496	0.253	<.001	11	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.765	.010	6	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SMYD3 tumor-vs-normal RNA expression · all SMYD3 data types